Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.53 |
| ▸ | ITGAV | P06756 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22310562 | 0.88 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL1295258 | 0.85 | ITGB3 (0.48) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL2568966 | 0.84 | ITGB3 (0.47) | ITGB3ITGA2B | |
| SCHEMBL25547122 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BTHRB | |
| SCHEMBL20060901 | 0.81 | GPR119 (0.61) | — | |
| Hydrochloric Acid SCHEMBL31752567 | 0.79 | CHEK2 (0.53) | ITGB3ITGA2B | |
| SCHEMBL22264119 | 0.78 | THRB (0.64) | THRB | |
| SCHEMBL20503245 | 0.78 | THRB (0.64) | THRB | |
| SCHEMBL1856929 | 0.78 | PARP10 (0.50) | — | |
| SCHEMBL9590251 | 0.77 | THRB (0.55) | ITGB3ITGA2BTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | ITGB3 1968/4885ITGA2B 2498/4885ITGAV 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.